Keiichi Shirasaki, Keiko Taguchi, Michiaki Unno, Hozumi Motohashi, Masayuki Yamamoto – 17 January 2014 – Hepatectomy is a standard therapy that allows liver cancer patients to achieve long‐term survival. Preceding hepatectomy, portal vein embolization (PVE) is frequently performed to increase the remnant liver size and reduce complications. Although the clinical importance of PVE is widely accepted, molecular mechanisms by which PVE leads to compensatory hypertrophy of nonembolized lobes remain elusive.

Francesco Salerno, Valentina Monti – 15 January 2014

Jia‐Hao Jiang, Yan‐Feng Liu, Ai‐Wu Ke, Fang‐Ming Gu, Yao Yu, Zhi Dai, Qiang Gao, Guo‐Ming Shi, Bo‐Yi Liao, You‐Hua Xie, Jia Fan, Xiao‐Wu Huang, Jian Zhou – 15 January 2014 – Virus‐induced hepatocarcinogenesis involves a series of histological developmental processes with the stepwise acquisition of several genetic changes that are necessary for the malignant transformation of hepatocytes. Although genetic alterations are known to be involved in the pathogenesis of hepatocellular carcinoma (HCC), little is known about the contributions of specific genes to this process.

Stefano Romeo, Luca Valenti, Eric Trépo, Christophe Moreno, Pierre Nahon, Pierre Deltenre – 15 January 2014

Jae Ho Lee, Gha Young Lee, Hagoon Jang, Sung Sik Choe, Seung‐Hoi Koo, Jae Bum Kim – 15 January 2014 – Sterol regulatory element binding protein1c (SREBP1c) is a key transcription factor for de novo lipogenesis during the postprandial state. During nutritional deprivation, hepatic SREBP1c is rapidly suppressed by fasting signals to prevent lipogenic pathways. However, the molecular mechanisms that control SREBP1c turnover in response to fasting status are not thoroughly understood.

William O. Osburn, Anna E. Snider, Brittany L. Wells, Rachel Latanich, Justin R. Bailey, David L. Thomas, Andrea L. Cox, Stuart C. Ray – 15 January 2014 – The contribution of humoral immune responses to spontaneous control of hepatitis C virus (HCV) infection remains unclear. We assessed neutralizing antibody (nAb) responses during acute HCV infection to determine whether infection outcome is associated with the nAb response, specifically, its timing or breadth (neutralization of multiple genotype‐matched variants).

Francesco Salerno, Valentina Monti – 15 January 2014

Emeric Limagne, Vanessa Cottet, Alexia Karen Cotte, Samia Hamza, Patrick Hillon, Norbert Latruffe, Dominique Delmas, for the CiRCE Study Group – 15 January 2014

Chien‐Hsieh Chiang, Long‐Teng Lee, Shou‐Hung Hung, Wen‐Yuan Lin, Hui‐Fang Hung, Wei‐Shiung Yang, Pei‐Kun Sung, Kuo‐Chin Huang – 15 January 2014 – Limited data exist regarding metabolic risk factors for deaths from hepatocellular carcinoma (HCC) in aging individuals. We investigated the association between diabetes, dyslipidemia, and HCC mortality in those aged 40 years or more (middle‐aged and elderly).

Marianna Hösel, Julie Lucifora, Thomas Michler, Gisela Holz, Marion Gruffaz, Stephanie Stahnke, Fabien Zoulim, David Durantel, Mathias Heikenwalder, Dirk Nierhoff, Rachel Millet, Anna Salvetti, Ulrike Protzer, Hildegard Büning – 14 January 2014 – Gene therapy has become an accepted concept for the treatment of a variety of different diseases. In contrast to preclinical models, subjects enrolled in clinical trials, including gene therapy, possess a history of infection with microbes that may influence its safety and efficacy.